Fundraising FoxEshelman Ventures, LLC — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2.
BiotechHealthtechDurham, US
Patrick Roberts(Executive Officer and member of the Board of Managers.)in
BoardFredric N. Eshelman(Executive Officer and member of the Board of Managers.)Sid Subramony(Member of the Board of Managers.)Norman Sharpless(Member of the Board of Managers.)
PartnerFred Eshelman· solo GP
Co-investorsCape Fear BioCapitalHatteras Venture PartnersHatteras
Paradigm Therapeutics is a biopharmaceutical company developing Zorblesia (SD-101), a proprietary topical whole-body therapy for treating the wounds, lesions, and infections associated with all subtypes of Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder.
BiotechHealthtechMedical DevicesMt Pleasant, US
Robert Ryan(Dr.)
PartnerFred Eshelman· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.